Exact Sciences
EXAS
$59.67
Share price
-5.65%
Change (1 day)
-9.88%
Change (1 year)
Categories
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.
P/S ratio for Exact Sciences (EXAS)
P/S ratio as of April 2024 (TTM): 4.59
According to Exact Sciences's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.59244. At the end of 2023 the company had a P/S ratio of 5.35.
P/S ratio history for Exact Sciences from 2002 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 5.35 | 26.81% |
| 2022 | 4.22 | -44.82% |
| 2021 | 7.65 | -42.76% |
| 2020 | 13.4 | -14.23% |
| 2019 | 15.6 | -8.92% |
| 2018 | 17.1 | -27.68% |
| 2017 | 23.6 | 62.27% |
| 2016 | 14.6 | -35.59% |
| 2015 | 22.6 | -98.33% |
| 2014 | > 1000 | 571.18% |
| 2013 | 202 | 23.39% |
| 2012 | 163 | 58.2% |
| 2011 | 103 | 76.87% |
| 2010 | 58.4 | 130.63% |
| 2009 | 25.3 | |
| 2008 | N/A | -100% |
| 2007 | 29.8 | 86.63% |
| 2006 | 16.0 | 16.05% |
| 2005 | 13.7 | -32.61% |
| 2004 | 20.4 | -69.71% |
| 2003 | 67.4 | -70.75% |
| 2002 | 230 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 2.31 | -49.69% | 🇫🇷 France |
 Veracyte VCYT | 4.14 | -9.91% | 🇺🇸 USA |
 Antares Pharma ATRS | N/A | N/A | 🇺🇸 USA |
 Myriad Genetics MYGN | 2.24 | -51.27% | 🇺🇸 USA |
 Biocept
BIOC | -0.3324 | -107.24% | 🇺🇸 USA |